CME Corner

This activity has expired. CME/CE credit is no longer available and the following content may not be available or may not be up-to-date. For a list of current activities that offer CME/CE credit, click here.

Program Detail

Release Date: April-02-15
Credit Expiration Date: April-02-16


Program Director 
Kathy S. Albain, MD, FACP, FASCO
Professor of Medicine Division of Hematology/Oncology
Loyola University
Chicago Stritch School of Medicine
Director, Breast Clinical Research Program
Director, Thoracic Oncology Program
Cardinal Bernardin Cancer Center
Maywood, IL

Additional Faculty Contributors
Suzanne A. W. Fuqua, PhD

Professor of Medicine
Breast Center
Baylor College of Medicine
Houston, TX

Mary L. (Nora) Disis, MD
Department of Medicine
Division of Oncology
University of Washington
Seattle, WA  

Rowan T. Chlebowski, MD, PhD, FASCO
Professor of Medicine 
David Geffen School of Medicine at UCLA 
Los Angeles, CA 
Chief, Division of Medical Oncology/Hematology 
Harbor-UCLA Medical Center 
Torrance, CA 

Hope S. Rugo, MD
Professor of Medicine
Director, Breast Oncology and Clinical Trials Education
University of California, San Francisco
Helen Diller Family Comprehensive Cancer Center
San Francisco, CA 

Ian E. Krop, MD, PhD
Senior Physician 
Dana-Farber Cancer Institute
Assistant Professor of Medicine 
Harvard Medical School
Boston, MA

David M. Euhus, MD, FACS
Professor of Surgery
Chief, Breast Surgery Section
Division of Surgical Oncology
Johns Hopkins Hospital
Baltimore, MD

Credit Hours

4.5 AMA PRA Category 1 CreditsTM.


Online Presentation

Program Description

This critical review of results presented at the December 2014 San Antonio Breast Cancer Symposium includes neoadjuvant and adjuvant therapy, endocrine plus targeted strategies for early and metastatic disease, triple negative and anti-HER2 subtype updates, immune therapy, presurgical window trials, translational science, local-regional disease, prevention and survivorship.


New Directions in Translational Molecular Research
Suzanne Fuqua, PhD

Emerging Immunotherapies for Breast Cancer
Mary L. (Nora) Disis, MD

Insights into Prevention and Survivorship
Rowan Chlebowski, MD, PhD

Advances from Neoadjuvant and Presurgical Window Studies
Kathy S. Albain, MD

Perspectives on Adjuvant Systemic Therapy
Hope Rugo, MD

Evolving Strategies for Metastatic Disease (ER+, HER2+, and TNBC)
Ian Krop, MD PhD

Updates on Local-Regional Therapies
David Euhus, MD

Target Audience

This educational activity is directed toward medical, surgical, and radiation oncologists, pathologists, basic scientists, and others interested in the diagnosis and treatment of patients with breast cancer. Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of breast cancer are also invited to participate.

Note: This activity was originally presented as a live symposium on February 7, 2015. If you received credit for participating in the live activity, you are not eligible to receive credit for this online release.

Learning Objectives

Upon completion of this knowledge-based educational activity, the participant should be able to:

  1. Discuss emerging data on and recent advances in the treatment of patients with breast cancer and integrate key findings into clinical practice.


Faculty Disclosure of Financial Relationships
Kathy S. Albain, MD
Advisory Board: Genentech, bioTheranostics, NanoString Technologies
Research Support: AbbVie, Genomic Health

Suzanne Fuqua, PhD:
No relevant financial relationships with any commercial interests

Mary L. (Nora) Disis, MD:
Honoraria: VentiRx, Emergent BioSolutions, Celgene, EMD Serono, Inc.
Stock: VentiRx, Epiphany Biosciences

Rowan Chlebowski, MD, PhD
Consultant: Novartis, Pfizer Inc., Genentech, Amgen
Speaker: Novartis

Hope Rugo, MD:
Speaker: Genomic Health

Ian Krop, MD PhD:
Research Support: Genentech

David Euhus, MD:
No relevant financial relationships with any commercial interests

Imedex, LLC Staff Disclosure of Financial Relationships
Imedex, LLC is a subsidiary of AmerisourceBergen Company. All Imedex staff members who are in a position to control content of this activity have no financial relationships with any commercial interests, except for the following individuals:

Chris Bolwell owns shares of stock of GlaxoSmithKline and AmerisourceBergen Company.

Imedex, LLC is an independent provider of continuing medical education. Imedex, LLC has no proprietary or financial interest in medical or healthcare products over which the FDA has regulatory authority.

MCM Education Staff Disclosure of Financial Relationships
All MCM Education staff members who are in a position to control content of this activity have no financial relationships with any commercial interests.

Unapproved and Investigational Uses of Drugs and Devices
This activity may contain information about experimental and other uses of drugs or devices that are not currently approved by the Food and Drug Administration (FDA) of the United States. Participants are encouraged to consult the FDA-approved product labeling for any drug or device mentioned in this program before use. The opinions expressed in this document are the opinions of the abstract authors and do not necessarily reflect the opinions of Imedex, LLC.

About Imedex LLC
Imedex is a brand and assumed name used by Imedex, LLC (hereby referred to as Imedex). Imedex is solely responsible for this agendaís content. Although Imedex attempts to ensure that the information in our program is accurate and timely, matters and opinions discussed and/or presented with respect to clinical matters are those of the discussion participants only, and not necessarily those of Imedex. Moreover, although Imedex attempts to identify and integrate the most qualified medical professionals in our program, TO THE FULLEST EXTENT PERMITTED BY LAW, IMEDEX EXPRESSLY DISCLAIM ALL WARRANTIES, EITHER EXPRESS OR IMPLIED, STATUTORY OR OTHERWISE, INCLUDING BUT NOT LIMITED TO THE IMPLIED WARRANTIES OF MERCHANTABILITY, NON-INFRINGEMENT OF THIRD PARTIESí RIGHTS, AND FITNESS FOR A PARTICULAR PURPOSE, WITH RESPECT TO THE CONTENT PRESENTED. IMEDEX FURTHER MAKES NO REPRESENTATIONS OR WARRANTIES ABOUT THE ACCURACY, RELIABILITY, COMPLETENESS OR TIMELINESS OF THE CONTENT OR ANY MATERIAL PRESENTED.

In addition, the material presented and related discussions are not intended to be medical advice, and the presentation or discussion of such material is not intended to create and does not establish a physician-patient relationship. Medical advice of any nature should be sought from an individualís own physician.

Neither Imedex nor any of its subsidiaries or affiliates is affiliated with or formally endorsed by a medical society.

Credit Statements

Physicians: This activity has been planned and implemented in accordance with the requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Imedex, MCM Education, and Loyola University Chicago. Imedex is accredited by the ACCME to provide continuing medical education for physicians.

Imedex designates this enduring activity for a maximum of 4.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants: AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 CreditsTM from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 4.5 hours of Category 1 credit for completing this program.

Commercial Support Statements

This activity is supported by educational grants from Puma Biotechnology, Celgene Corporation, Eisai Inc., and Genomic Health.

Certificate Fee


By clicking START PROGRAM I acknowledge that I have read the CME/CE information above.

Main Menu